Evidence map›Paper›PMID 36600489›Full record

SynthesisDrug and alcohol review2023

Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis.

Anjalee Syangbo, Matthew Hickman, Samantha Colledge-Frisby, Janni Leung, Jason Grebely, Sarah Larney, Louisa Degenhardt, Adam Trickey

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drug and alcohol review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Anjalee SyangboPopulation Health Sciences, University of Bristol, Bristol, UK.
Matthew HickmanPopulation Health Sciences, University of Bristol, Bristol, UK.
Samantha Colledge-FrisbyNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Janni LeungNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0001-5816-2959
Jason GrebelyKirby Institute, UNSW Sydney, Sydney, Australia.
Sarah LarneyNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-5602-4963
Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-8513-2218
Adam TrickeyPopulation Health Sciences, University of Bristol, Bristol, UK.ORCID 0000-0003-3462-2898
UNSW Sydney · AUUniversity of Bristol · GBThe University of Queensland · AU

Funding

Wellcome TrustWellcome Trust 222770/Z/21/Z
6 · The paper itself

Abstract

introductionGlobally, hepatitis B virus (HBV) is a leading cause of liver disease. People who inject drugs (PWID) are at greater risk than the general population of contracting HBV. This risk could depend on societal factors in different countries. We investigated the associations between country-level chronic HBV prevalence in PWID with national indicators of development and prevalence of HIV and hepatitis C virus (HCV).

methodsWe used global systematic review data on chronic HBV prevalence (hepatitis B surface antigen-positive) among PWID and country-level sociodemographic characteristics from online databases. National random-effects meta-analysis estimates of HBV prevalence were the outcome in linear regression models testing for associations with country-level characteristics.

resultsThe study included 131,710 PWID from 304 estimates in 55 countries: the pooled HBV prevalence among PWID in the countries analysed was 4.5% (95% CI 3.9-5.1), the highest regional pooled prevalence was in East and Southeast Asia (17.6% [13.3-22.3]), and the lowest was in Western Europe (1.7% [1.4-2.1]). In multivariable models, no indicators of development were associated with HBV prevalence, but there was evidence of positive associations between HBV prevalence in the general population and among PWID, and evidence of HIV and HCV prevalence in PWID being associated with HBV prevalence in PWID: multivariable coefficients 0.03 (95% CI 0.01-0.04); p < 0.001, and 0.01 (95% CI 0.00-0.03); p = 0.01, respectively. DISCUSSION AND

conclusionsHBV prevalence among PWID was associated with HIV and HCV prevalence among PWID and background HBV prevalence in the general population, highlighting the need for improving harm reduction in PWID and implementation of HBV vaccination, especially where HBV is endemic.

Indexed as

Drug UsersHepatitis BHepatitis B, ChronicHepatitis CHIV InfectionsSubstance Abuse, IntravenousHepacivirusHepatitis B virusHumansPrevalenceecologicalhepatitis B viruspeople who inject drugsprevalence

Identifiers

PMID36600489
PMCPMC10728688
OpenAlexW4313499086

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.